Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (522)
Published in
Speakers
My lab focuses on the development of new treatment paradigms for lung cancer using three primary tools: genetic, epigenetic, and transcriptomic analyses; functional genomics using CRISPR-Cas9; and, high-fidelity patient-derived models of lung cancer. In addition to my primary research focus, I direct the Perlmutter Cancer Center Preclinical Therapeutics Program, which acquires viable human tumor cells from the clinic for the development of cancer models and tests experimental cancer therapeutics in the preclinical setting.
Published in
Speakers
Dr. Paz-Ares (MD, Ph.D.) is currently Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at National Oncology Research Center, all in Madrid.
He graduated with a degree in Medicine from the Universidad Autónoma de Madrid, in 1986, and was trained as a resident in Medical Oncology at Hospital 12 de Octubre (1988-2001). In 1993, he completed a Ph.D. in Medicine at the Universidad Autónoma de Madrid. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, (1993– 1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995.
Before the current position he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014), Head of the Pharmacology Unit and responsible for Early Clinical Studies of Thoracic and Genitourinary Tumours at the University Hospital "12 de Octubre" in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).
Luis Paz-Ares’s research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 340 articles in peer review journals including New England Journal of Medicine, Lancet, Lancet Oncology, Nature Medicine, Journal of Clinical Oncology and many others. He has served as a member of several committees, including ASCO and ESMO meeting Scientific Committees, European Organisation for Research and Treatment of Cancer Protocol Review Committee and Audit Committee, the Spanish Agency of Medicines and Medical Devices and the European Medicines Agency. He is the Chief Medical Officer of the AECC where he also seats at the Board.
Published in
Speakers
Dr. Owonikoko is a Professor and Vice Chair for Faculty Development in the Department of Hematology and Medical Oncology at Emory University. He is also a Georgia Research Alliance Distinguished Cancer Scientist. He received his medical degree from the Obafemi Awolowo University, Ile-Ife Nigeria in 1991 and a doctoral degree in Anatomic Pathology from the Heinrich Heine University, Dusseldorf, Germany in 2000. He was a postdoctoral research fellow at the Johns Hopkins University in Baltimore, USA from 2000 to 2002. He completed Internal Medicine residency training at the Graduate Hospital, Drexel University in Philadelphia in 2005 followed by a clinical fellowship in Hematology/Medical Oncology at the University of Pittsburgh in 2008. He has been on faculty at Emory University since 2008 and has focused his translational research activities on lung cancer, thyroid cancer and early phase drug development. Dr. Owonikoko has received peer-reviewed grant funding from the NIH, DOD and Georgia Cancer Coalition. He has published over 230 peer-reviewed manuscripts in high impact journals including New England Journal of Medicine, Cell, Science, Nature, CA Cancer Journal, Cancer Cell, Lancet Oncology, JCO, Cancer Discovery, Nature Communications, Oncogene, Cancer Research, Clinical Cancer Research and Journal of Thoracic Oncology.
Published in
Speakers
Matthew G. Oser MD, PhD, is a Physician-Scientist in the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute (DFCI) and an Assistant Professor of Medicine at Harvard Medical School. After earning his MD and PhD from the Albert Einstein College of Medicine, Dr. Oser completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed medical oncology fellowship training at the Dana-Farber Cancer Institute/Massachusetts General Hospital combined program, and performed his post-doctoral work in Dr. William G. Kaelin Jr’s laboratory at DFCI. Since 2019, he is the principal investigator of his own laboratory at DFCI.
Dr. Oser’s research focuses on using CRISPR/Cas9 to understand mechanisms that control neuroendocrine differentiation in SCLC and to identify novel targeted therapies for SCLC. Dr. Oser has been the recipient of a Lung Cancer Research Foundation Career Development Award, a NIH K08 career development award, and a Damon Runyon Clinical Investigator Award.
Published in
Speakers
Dr. Oliver received her PhD from Duke University in 2005 in Pharmacology and Cancer Biology as a graduate student in Dr. Rob Wechsler-Reya's lab. She completed a Postdoctoral Fellowship (2006-2011) in Dr. Tyler Jack's lab at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT), Boston, MA. Dr. Oliver joined the University of Utah and Huntsman Cancer Institute in 2011. She is now Associate Professor with tenure and a Huntsman Cancer Institute (HCI) Endowed Chair in Cancer Research in the Department of Oncological Sciences. Dr. Oliver is a co-leader of the Cell Response and Regulation (CRR) and co-leader of the Lung Cancer Disease Center at HCI. Dr. Oliver has received many awards including a National Science Foundation (NSF) graduate student fellowship, and two postdoctoral fellowships from ASPET-Merck and the Ludwig Foundation at MIT. As an independent investigator, she has received awards from the Damon Runyon Cancer Research Foundation, the V Foundation for Cancer Research, American Cancer Society, American Lung Association, and was honored with a William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation (LCRF).
Research: Dr. Oliver's research is devoted to understanding mechanisms of lung cancer biology with the goal of identifying novel therapeutic targets to improve patient outcome. As a graduate student at Duke, she studied the developmental origins of the childhood brain tumor, medulloblastoma, where she identified mechanisms of tumor progression in mouse models of the disease. As a postdoctoral fellow at MIT and as an independent investigator, she has developed novel mouse models of squamous and small cell lung cancer. Her work has contributed to our understanding of the Mdm2/p53 pathway, chemotherapy resistance mechanisms, and the functions of oncogenic transcription factors like Sox2, Nkx2-1, and Myc. Dr. Oliver’s laboratory integrates mouse genetics, molecular and cellular biology, biochemistry, single cell genomics, in vivo imaging, and preclinical therapeutics.
Teaching and Mentoring: Dr. Oliver has been active in graduate student and medical school teaching. Dr. Oliver's trainees have received a number of prestigious awards. These include the Susan Cooper Jones Postdoc of the Year Award, the James W. Prahl Memorial Graduate Student of the Year award, an NIH NCI F99/K00 Predoctoral to Postdoctoral Fellow Transition Award. In addition, Oliver lab trainees have won a number of travel awards including to Keystone Symposia and selection as a recipient to the 68th Annual Lindau Nobel Laureate meeting in Germany.
Published in
Speakers
Dr. Catherine Meador is a senior clinical fellow in the Dana-Farber/Mass General Brigham medical oncology fellowship program. Her primary research interests focus on the biology of initiation and progression of small cell lung cancer, as well as mechanisms of histologic transformation in lung cancer and the pathologic and clinical characteristics of mixed histology lung tumors.
Published in
Speakers
Dr. MacPherson is a Professor in the Division of Human Biology at Fred Hutch. His lab is focused on understanding the molecular underpinnings of small cell lung cancer (SCLC). The lab studies SCLC patient samples and employs genetically engineered mouse (GEM) models as well as patient-derived xenograft models to interrogate genes that drive SCLC initiation, progression and response to therapy. Building upon the Rb/p53-deleted mouse model developed by Berns’ group, his lab has generated GEM models with deletions in SCLC tumor suppressors such as Pten, Crebbp and Max and with overexpression of oncogenes such as MYCN. His lab employs GEM and PDX models in therapeutic studies to understand and improve responses to novel and to standard therapies for SCLC.
Published in
Speakers
Christine M. Lovly, MD, PhD is currently an Associate Professor of Medicine with tenure at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center. She received a B.A. in chemistry from Johns Hopkins University followed by M.D. and Ph.D. degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She then completed internal medicine residency and medical oncology subspecialty training at Vanderbilt University. During her final year of fellowship, she was the Jim and Carol O'Hare Chief Fellow. She started on faculty at Vanderbilt in July 2013 as a Physician Scientist, splitting her time between clinical care and laboratory research. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of cancer.
Dr. Lovly has received grant funding from NIH/NCI, Uniting Against Lung Cancer, the Conquer Cancer Foundation of the American Society of Clinical Oncology, the Sarcoma Foundation of America, the American Cancer Society, the Damon Runyon foundation, the LUNGevity foundation, the V Foundation, the American Association for Cancer Research, and Lung Cancer Foundation of America / International Association for the Study of Lung Cancer. She is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR). She is co-Editor-In-Chief for the website www.mycancergenome.org, a Vanderbilt initiated, freely available website which aims to provide health care practitioners, patient, and advocates with up-to-date information regarding genetically informed cancer medicine. Dr. Lovly is also an elected member of the American Society for Clinical Investigation (ASCI) and serves on the Editorial Board for Cancer Discovery. She serves on the Scientific Leadership Boards for the GO2 Foundation for Lung Cancer Research (where she also serves as SLB director), the LUNGevity Foundation, and the Lung Cancer Research Foundation. In 2021, she was awarded the ECOG-ACRIN Cancer Research Group Young Investigator Award.
Published in
Speakers
Dr. Benjamin Lok is a Clinician-Scientist at the Princess Margaret Cancer Centre and an Assistant Professor in the Departments of Radiation Oncology, Medical Biophysics, and the Institute of Medical Science, at the University of Toronto. He received his MD from New York University School of Medicine in 2012 followed by clinical residency with laboratory research training at Memorial Sloan Kettering Cancer Center. Since joining Princess Margaret in 2017, Dr. Lok has served as Staff Radiation Oncologist within the Lung Site Group. He leads a CIHR and NIH funded laboratory program with a mission to improve outcomes for lung cancer patients by understanding mechanisms of resistance and developing novel therapeutic strategies, particularly those related to DNA repair.
Published in
Speakers
